Abstract:Motivation: Currently there are no curative anticancer drugs, and drug resistance is often acquired after drug treatment. One of the reasons is that cancers are complex diseases, regulated by multiple signaling pathways and cross talks among the pathways. It is expected that drug combinations can reduce drug resistance and improve patients’ outcomes. In clinical practice, the ideal and feasible drug combinations are combinations of existing Food and Drug Administration-approved drugs or bioactive compounds that are already used on patients or have entered clinical trials and passed safety tests. These drug combinations could directly be used on patients with less concern of toxic effects. However, there is so far no effective computational approach to search effective drug combinations from the enormous number of possibilities. Results: In this study, we propose a novel systematic computational tool DrugComboRanker to prioritize synergistic drug combinations and uncover their mechanisms of action. We first build a drug functional network based on their genomic profiles, and partition the network into numerous drug network communities by using a Bayesian non-negative matrix factorization approach. As drugs within overlapping community share common mechanisms of action, we next uncover potential targets of drugs by applying a recommendation system on drug communities. We meanwhile build disease-specific signaling networks based on patients’ genomic profiles and interactome data. We then identify drug combinations by searching drugs whose targets are enriched in the complementary signaling modules of the disease signaling network. The novel method was evaluated on lung adenocarcinoma and endocrine receptor positive breast cancer, and compared with other drug combination approaches. These case studies discovered a set of effective drug combinations top ranked in our prediction list, and mapped the drug targets on the disease signaling network to highlight the mechanisms of action of the drug combinations. Availability and implementation: The program is available on request. Contact: stwong@tmhs.org

Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

An integrated computational strategy to predict personalized cancer drug combinations by reversing drug resistance signatures

DrugComboRanker: Drug Combination Discovery Based on Target Network Analysis

Systems Pharmacology-Based Precision Therapy and Drug Combination Discovery for Breast Cancer

Machine learning-driven exploration of drug therapies for triple-negative breast cancer treatment

A landscape of response to drug combinations in non-small cell lung cancer

Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy

Effective drug combinations in breast, colon and pancreatic cancer cells

An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine

Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations

Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies

How to Predict Effective Drug Combinations - Moving beyond Synergy Scores

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning

Prediction of Cancer Drug Combinations Based on Multidrug Learning and Cancer Expression Information Injection

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data